2024 Napa Valley Lung Cancer Conference

Santa Rosa, CA US
May 10, 2024 to May 11, 2024

This CME-accredited activity 2024 Napa Valley Lung Cancer Conference features leading experts in thoracic malignancies who will provide a comprehensive overview of current and emerging strategies for management of lung cancer (NSCLC, SCLC). The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with lung cancer. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in molecular testing and targeted-therapies for thoracic oncology. Expert faculty will aim to place the role of diagnostics, biomarkers and different therapeutic agents in clinical context and discuss how to utilize these tests and therapies to effectively contribute to patient care. 

Target Audience

  • Medical Oncologists
  • Surgeons
  • Radiation Oncologists,
  • Pathologists Oncology Fellows
  • Oncology Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Pharmacists

ORGANIZING COMMITTEE

Conference Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chair:

Jonathan Riess, MD - UC Davis 

Organizing Committee:

Deepti Behl, MD - Sutter Health

Ranjan Pathak, MD - Enloe Health

Heather Wakelee, MD, FASCO - Stanford University

VENUE INFORMATION 

A limited number of rooms have been booked at the Hyatt Regency Sonoma Valley at a discounted nightly rate of $229 per room for this conference's attendees and sponsors. Please book your room at this link here by April 9, 2024.  

Learning Objectives

  1. Review potentially actionable molecular abnormalities in lung cancer, and the appropriate testing and treatment for actionable alteration.
  2. Summarize efficacy and toxicities of immune checkpoint inhibitors, targeted therapy, and other chemotherapy agents in management of management of lung cancer.
  3. Identify the role of perioperative systemic therapy options in curative-intent treatment of NSCLC, including the role of chemotherapy, immune checkpoint inhibitors and targeted therapy.
  4. Integrate emerging evidence of cutting edge developments in precision oncology into treatment paradigms for treatment of thoracic malignancies.

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:

Course summary
Available credit: 
  • 8.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.00 Contact Hours.
Course opens: 
12/06/2021
Course expires: 
08/31/2024
Event starts: 
05/10/2024 - 7:00am PDT
Event ends: 
05/11/2024 - 4:00pm PDT
Cost:
$350.00

Day 1 - May 10th, 2024

All times are listed in Pacific Daylight Time (PDT)

03:00 PM - 03:45 PM  Registration, Networking, & Exhibits


03:45 PM - 04:00 PM  Opening Remarks


04:00 PM - 05:30 PM  Session 1: The Evolution of Treatment for EGFR Mutated Lung Cancer

Moderators: Jonathan Riess

04:00 PM - 04:15 PM  Optimal 1L Therapy for Advanced EGFR Mutant Lung Cancer (Common Mutations)

04:15 PM - 04:30 PM  Sequencing Therapy 2L and Beyond in EGFR Mutant NSCLC

04:30 PM - 04:45 PM  EGFR Exon 20 ins and Uncommon Mutations in NSCLC- Jonathan Riess, MD

04:45 PM - 05:00 PM  Resistance Mechanisms and Lineage Plasticity in EGFR Mutant Lung Cancer

05:00 PM - 05:15 PM  Targeting HER2 in NSCLC- Jennifer Marie Suga, MD

05:15 PM - 05:30 PM  Panel Discussion


05:30 PM - 06:30 PM  Session 2: New Targets and Treatments in Oncogene Driven Lung Cancer

Moderators: 

05:30 PM - 05:45 PM  Evolution of ALK and ROS1 Treatments in Lung Cancer- Mohana Roy, MD

05:45 PM - 06:00 PM  Targeting Uncommon Oncogene Drivers (MET, RET, and Others)- Nathaniel Myall, MD

06:00 PM - 06:15 PM  Next Generation KRAS Inhibitors 

06:15 PM - 06:30 PM  Panel Discussion


06:30 PM - 07:15 PM  Reception, Networking, & Exhibits 


Day 2 - May 11th, 2024

07:00 AM - 08:00 AM  Breakfast & Exhibits


08:00 AM - 09:00 AM  Session 3: Immunotherapy and ADCs in Advanced Lung Cancer - What's Next? 

Moderators: 

08:00 AM - 08:15 AM  New Biomarkers for IO Agents in Lung Cancer- Surbhi Singhal, MD

08:15 AM - 08:30 AM  Cellular Therapies in Lung Cancer

08:30 AM - 08:45 AM  Novel IO Agents in NSCLC

08:45 AM - 09:00 AM  Panel Discussion


09:00 AM - 09:20 AM  Break & Exhibits


09:20 AM - 10:50 AM  Session 4: Perioperative Treatment in Lung Cancer

Moderators: Heather Wakelee

09:20 AM - 09:35 AM  Perioperative Therapy in Lung Cancer: How Far We Have Come and Where Are We Going- Heather Wakelee, MD

09:35 AM - 09:50 AM  Neoadjuvant Chemo-IO Only

09:50 AM - 10:05 AM  Neoadjuvant + Adjuvant

10:05 AM - 10:20 AM  When is Adjuvant Chemotherapy +/- Immunotherapy Preferred Over Neoadjuvant Chemo-Immunotherapy

10:20 AM - 10:35 AM  Integrating Targeted Therapy in Early Stage and Locally Advanced NSCLC

10:35 AM - 10:50 AM  Panel Discussion


10:50 AM - 11:10 AM  Break & Exhibits


11:10 AM - 12:10 PM  Session 5: Radiation in Multimodality Therapy in Lung Cancer

Moderators: 

11:10 AM - 11:25 AM  Is Radiation a Sensitizer to Immunotherapy in Lung Cancer

11:25 AM - 11:40 AM  Immunotherapy Optimization and Selection in Stage III Disease

11:40 AM - 11:55 AM  ctDNA for MRD Monitoring in Curative Lung Cancer

11:55 AM - 12:10 PM Panel Discussion


12:10 PM - 01:10 PM  Lunch & Exhibits


01:10 PM - 02:25 PM  Session 6: Latest and Greatest in Squamous Lung Cancer, Small Cell Lung Cancer, and Other Lung Neuroendocrine Tumors

Moderators: 

01:10 PM - 01:25 PM  Bringing Molecular Classification to the Clinic in SCLC

01:25 PM - 01:40 PM  Advances in Targeting SCLC

01:40 PM - 01:55 PM  Advances and Treatment of Lung Neuroendocrine Tumors (not SCLC)

01:55 PM - 02:10 PM  New Targets in Squamous NSCLC- Shiruyeh Schokrpur, MD, PhD

02:10 PM - 02:25 PM  Panel Discussion


02:25 PM - 03:10 PM  Session 7: New Targets in Lung Cancer

Moderators: 

02:25 PM - 02:40 PM  ABCs of ADCs in Lung Cancer

02:40 PM - 02:55 PM  When Do I Use Dual Immune Checkpoint Blockade in NSCLC? 

02:55 PM - 03:10 PM  Panel Discussion


03:10 PM - 03:15 PM  Adjourn

Hyatt Regency Sonoma Valley
170 Railroad St
Santa Rosa, CA 95401
United States

A limited number of rooms have been booked at the Hyatt Regency Sonoma Valley at a discounted nightly rate of $229 per room for this conference's attendees and sponsors. Please book your room at this link here by April 9, 2024.  

 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Available Credit

  • 8.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme .

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.